GAL and Arthritis: Injection of syngeneic fibroblasts genetically engineered to secrete Gal-1, or daily administration of recombinant Gal-1 suppressed clinical and histopathological manifestations of arthritis and promoted a shift toward a Th2-mediated anti-inflammatory response (46).